Novartis AG logo

NOVN - Novartis AG Share Price

CHF79.49 0.4  0.5%

Last Trade - 07/05/21

Large Cap
Market Cap £141.76bn
Enterprise Value £165.95bn
Revenue £35.70bn
Position in Universe 4th / 1050
Unlock NOVN Revenue
Relative Strength (%)
1m -1.97%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.70%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
50,359 49,386 43,361 46,017 48,624 49,898 52,044 54,079 -0.2%
-29.7 -5.1 +5.7 +14.8 +2.0 +13.9 +43.3 +7.97
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, NovartisAG revenues decreased less than 1% to $12.69B. Net incomedecreased 5% to $2.06B. Revenues reflect InnovativeMedicines segment increase of 4% to $10.1B, Asia / Africa /Australasia segment increase of 6% to $2.68B, Europesegment increase of 2% to $4.91B, Canada and Latin Americasegment increase of 1% to $839M, also reflect Sandozsegment decrease of 9% to $2.31B.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for NOVN
Graphical History


NOVN Revenue Unlock NOVN Revenue

Net Income

NOVN Net Income Unlock NOVN Revenue

Normalised EPS

NOVN Normalised EPS Unlock NOVN Revenue

PE Ratio Range

NOVN PE Ratio Range Unlock NOVN Revenue

Dividend Yield Range

NOVN Dividend Yield Range Unlock NOVN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NOVN EPS Forecasts Unlock NOVN Revenue
Profile Summary

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated March 1, 1996
Public Since May 7, 2001
No. of Shareholders: 176,319
No. of Employees: 110,000
Sector Healthcare
Industry Pharmaceuticals
Index FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSEurofirst 300 Ex UK, FTSE Global 100,
Exchange SIX Swiss Exchange
Shares in Issue 2,245,088,809
Free Float (0.0%)
Eligible for
NOVN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NOVN
Upcoming Events for NOVN
Tuesday 11th May, 2021
Novartis AG at Bank of America Global Research Healthcare Conference (Virtual)
Tuesday 18th May, 2021
Novartis AG Cardiovascular Update Call
Tuesday 18th May, 2021
Novartis AG at Berenberg US Conference (Virtual)
Monday 24th May, 2021
Novartis AG at UBS Global Healthcare Virtual Conference
Thursday 3rd June, 2021
Novartis AG at Jefferies Healthcare Conference (Virtual)
Friday 4th June, 2021
Novartis AG at Sanford C Bernstein Strategic Decisions Conference (Virtual)
Tuesday 8th June, 2021
Novartis AG Oncology Update Call
Wednesday 9th June, 2021
Novartis AG at Goldman Sachs Global Healthcare Conference (Virtual)
Tuesday 22nd June, 2021
Novartis AG Iptacopan (LNP023) Update Call
Wednesday 23rd June, 2021
Novartis AG at Guggenheim Biopharma's Next Decade Virtual Conference
Wednesday 21st July, 2021
Q2 2021 Novartis AG Earnings Release
Tuesday 26th October, 2021
Q3 2021 Novartis AG Earnings Release
Frequently Asked Questions for Novartis AG
What is the Novartis AG share price?

As of 07/05/21, shares in Novartis AG are trading at CHF79.49, giving the company a market capitalisation of £141.76bn. This share price information is delayed by 15 minutes.

How has the Novartis AG share price performed this year?

Shares in Novartis AG are currently trading at CHF79.49 and the price has moved by -4.44% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Novartis AG price has moved by -25.02% over the past year.

What are the analyst and broker recommendations for Novartis AG?

Of the analysts with advisory recommendations for Novartis AG, there are there are currently 7 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Novartis AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Novartis AG next release its financial results?

Novartis AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Novartis AG dividend yield?

The Novartis AG dividend yield is 3.84% based on the trailing twelve month period.

Does Novartis AG pay a dividend?

Last year, Novartis AG paid a total dividend of 3.39, and it currently has a trailing dividend yield of 3.84%. Looking ahead, Novartis AG has not announced an ex-dividend date yet.

When does Novartis AG next pay dividends?

Novartis AG has yet to annouce their ex-dividend date. The historic dividend yield on Novartis AG shares is currently 3.84%.

How do I buy Novartis AG shares?

To buy shares in Novartis AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Novartis AG?

Shares in Novartis AG are currently trading at CHF79.49, giving the company a market capitalisation of £141.76bn.

Where are Novartis AG shares listed? Where are Novartis AG shares listed?

Here are the trading details for Novartis AG:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: NOVN
What kind of share is Novartis AG?

Based on an overall assessment of its quality, value and momentum, Novartis AG is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Novartis AG share price forecast 2021?

Shares in Novartis AG are currently priced at CHF79.49. At that level they are trading at 19.11% discount to the analyst consensus target price of 0.00.

Analysts covering Novartis AG currently have a consensus Earnings Per Share (EPS) forecast of 6.313 for the next financial year.

How can I tell whether the Novartis AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novartis AG. Over the past six months, the relative strength of its shares against the market has been -9.7%. At the current price of CHF79.49, shares in Novartis AG are trading at -0.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Novartis AG PE Ratio?

The Novartis AG PE ratio based on its reported earnings over the past 12 months is 20.14. The shares are currently trading at CHF79.49.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Novartis AG?

Novartis AG's management team is headed by:

Joerg Reinhardt - NEC
Enrico Vanni - NVC
Susanne Schaffert - EXB
Harry Kirsch - CFO
Steven Baert - CHO
Nancy Andrews - NID
Ton Buechner - NID
James Bradner - EXB
Vasant Narasimhan - CEO
Shannon Klinger - EXB
Klaus Moosmayer - CCO
Steffen Lang - CTO
John Tsai - EXB
Richard Saynor - EXB
Patrice Bula - NID
Who are the major shareholders of Novartis AG?

Here are the top five shareholders of Novartis AG based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.39% (108.2m shares)
Sandoz Family Individual Investor
Percentage owned: 3.61% (89.1m shares)
UBS Asset Management (Switzerland) Investment Advisor
Percentage owned: 2.3% (56.8m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.3% (56.8m shares)
Statens Pensjonsfond Utland Mutual Fund
Percentage owned: 2.26% (55.7m shares)
Similar to NOVN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.